SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea flag South Korea · Delayed Price · Currency is KRW
79,400
-4,000 (-4.80%)
Sep 11, 2026, 3:30 PM KST

SK Biopharmaceuticals Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
400,956266,950240,738-32,883-139,43164,846
Depreciation & Amortization
15,90516,94717,42815,31712,98411,642
Loss (Gain) From Sale of Assets
186.55194.81-171.0218.7211.283.02
Asset Writedown & Restructuring Costs
-597.33-597.33-6,808172.96-
Loss (Gain) From Sale of Investments
-11,1692,7571,396-12,2432,858-2,208
Loss (Gain) on Equity Investments
26,68034,30731,25311,53514,92734,544
Stock-Based Compensation
-601.863,6337,5113,23360.66416.71
Other Operating Activities
-94,144-111,576-170,591-10,34514,161-132,402
Change in Accounts Receivable
-84,211-58,344-37,064-52,456-13,169-41,610
Change in Inventory
12,91210,880-8,593-13,708-38,693-29,459
Change in Accounts Payable
5,2106,036940.7-20,7116,965607.69
Change in Other Net Operating Assets
-22,6475,14412,05311,232-20,767748.38
Operating Cash Flow
248,480176,33494,900-94,201-159,920-92,872
Operating Cash Flow Growth
140.71%85.81%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-7,825-6,892-1,395-2,385-4,911-4,316
Sale of Property, Plant & Equipment
-----11.24
Cash Acquisitions
---31,043--
Sale (Purchase) of Intangibles
-23,354-22,119-10,726-864.17-1,050-1,676
Investment in Securities
-10,553-4,3673,506198,587-89,691265,618
Other Investing Activities
-2,429-2,068-2,340-1,104-10.78-639.56
Investing Cash Flow
-44,247-35,420-10,941225,273-95,714258,971

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-6.94100,000---
Long-Term Debt Issued
----141,751-
Total Debt Issued
6.946.94100,000-141,751-
Short-Term Debt Repaid
--50,007-50,000---
Long-Term Debt Repaid
--106,678-54,498-5,575-5,477-4,827
Total Debt Repaid
-32,314-156,685-104,498-5,575-5,477-4,827
Net Debt Issued (Repaid)
-32,307-156,678-4,498-5,575136,274-4,827
Other Financing Activities
-6,284-0.3812,198-1,360180.69
Financing Cash Flow
-38,591-156,678-4,4986,623134,914-4,646

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-6,659727.943,646-2,054-1,1435,135
Miscellaneous Cash Flow Adjustments
-----0
Net Cash Flow
158,983-15,03683,107135,640-121,863166,589

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
240,655169,44293,505-96,586-164,831-97,188
Free Cash Flow Growth
138.28%81.21%----
Free Cash Flow Margin
27.94%23.97%17.08%-27.22%-66.96%-23.21%
Free Cash Flow Per Share
3072.742163.641193.98-1233.34-2104.77-1241.01
Levered Free Cash Flow
112,033112,02833,476-54,562-108,21051,274
Unlevered Free Cash Flow
115,522116,83440,152-49,387-105,88851,865

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
4,2576,4449,4998,1423,488844.19
Cash Income Tax Paid
8,25120,03512,1548,1264,6816,160
Change in Working Capital
-88,735-36,283-32,663-75,643-65,664-69,713